Hemophilia Market Size to Reach US$ 22.3 Billion at 11.1% CAGR by 2028 | IMARC Group

The latest report by IMARC Group, titled "Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028". The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.

Hemophilia is a rare genetic disorder characterized by a deficiency or dysfunction of specific blood clotting factors, primarily factors VIII (in hemophilia A) or IX (in hemophilia B). This condition impairs the ability of the body to form clots, which are essential for stemming bleeding when blood vessels are injured. Hemophilia is typically inherited and occurs predominantly in males. Individuals with hemophilia are prone to prolonged bleeding, even from minor injuries, and may experience spontaneous bleeding into joints and muscles, which can lead to pain and joint damage over time. Managing hemophilia involves regular infusions of clotting factor concentrates to prevent or treat bleeding episodes.

Request Your Sample Report Now: https://www.imarcgroup.com/hemophilia-market/requestsample

Hemophilia Market Trends and Drivers:

The rising prevalence of hemophilia worldwide is propelling the market. The increase in the number of diagnosed cases has spurred research and development efforts to meet the growing demand for effective treatments. Additionally, another critical factor is the improving healthcare infrastructure and access to treatment in emerging economies. As these regions develop, more patients gain access to hemophilia care, leading to increased demand for clotting factor products. Other than this, collaborations and partnerships between pharmaceutical companies and research institutions are fostering the development of novel therapies and treatment regimens. Besides this, the increasing awareness about hemophilia and advocacy efforts by patient organizations are driving early diagnosis and treatment initiation. This heightened awareness not only improves patient outcomes but also boosts market growth. Moreover, advancements in medical technology and the development of innovative therapies are significant driving factors. These include the introduction of extended half-life factor concentrates and gene therapy, offering more convenient and long-lasting treatment options. These innovations not only enhance patient outcomes but also drive market expansion.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Type:

Hemophilia A
Hemophilia B
Hemophilia C
Others

Breakup by Treatment:

On-Demand
Prophylaxis

Breakup by Therapy:

Replacement Therapy
ITI Therapy
Gene Therapy

Market Breakup by Region:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

Competitive Landscape with Key Player:

Baxter International Inc.
Bayer AG
BioMarin Pharmaceutical Inc.
CSL Behring (CSL Limited)
F. Hoffmann-La Roche AG
Grifols S.A.
Kedrion S.p.A.
Novo Nordisk A/S
Octapharma AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited.

Explore full report with table of contents: https://www.imarcgroup.com/hemophilia-market

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.